Annual Report 2015 Active Biotech AB (publ)
April 29 2016 - 4:00AM
Active Biotech's Annual Report 2015 is now
available for download at www.activebiotech.com.
The Annual Report will only be digitally
distributed. The English version will be available within
short.
Lund, April 29, 2016
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
For further information,
please contact:
Hans Kolam, CFO
Tel +46 (0)46 19 20 44
Active Biotech AB
(publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties, is in pivotal Phase 3 development for
the treatment of relapsing remitting multiple sclerosis. Also,
laquinimod is in Phase 2 development for the treatment of primary
progressive multiple sclerosis and Huntington's disease.
Furthermore, commercial activities are conducted for the
tasquinimod, SILC, ANYARA and paquinimod projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 05
Active Biotech
is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act and/or
the Financial Instruments Trading Act. This information was
provided to the media for publication on April 29, 2016 at 10:00
a.m.
Annual Report 2015 Active Biotech
AB (publ)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#2007443
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
